Shanghai Henlius Biotech, Inc. (2696.HK) Comparison with companies in other sectors?

Shanghai Henlius Biotech, Inc. has a share price of 550.87M. You can analyze Shanghai Henlius Biotech, Inc. (2696.HK) competitors across different market sectors through stock heatmaps.

What are 2696.HK's NET and operating margins?

Shanghai Henlius Biotech, Inc. (2696.HK) operating margin is around 0.15, and net profit margin is approximately 0.14 as of the latest reports.

In what way does 2696.HK's earnings per share (EPS) trend reflect its financial momentum?

Shanghai Henlius Biotech, Inc. (2696.HK) EPS is 1.65 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Shanghai Henlius Biotech, Inc. is 40.00, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Shanghai Henlius Biotech, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Shanghai Henlius Biotech, Inc. like P/E which is 40.14, P/B which is 10.93, and PEG which is 3.99. Compare them with sector averages to evaluate if the stock is priced fairly.

Shanghai Henlius Biotech, Inc.

2696.HK•HKSE

Healthcare

Biotechnology

HK$66.45

HK$-3.55(-5.07%)

Shanghai Henlius Biotech, Inc. (2696.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$1.65

P/E Ratio

40.00

ROE

0.29%

Net Margin

0.14%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$36.36B

Shares OutstandingTotal number of shares issued

$550.87M

Book Value/ShareNet worth per share

$5.54

Revenue/ShareAnnual revenue per share

$10.53

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.65

Net MarginNet income as percentage of revenue

14.33%

Operating MarginOperating income as percentage of revenue

15.14%

ROEReturn on shareholders' equity

29.35%

ROAReturn on total assets

7.74%

ROCEReturn on capital employed

15.57%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.27

Cash/ShareCash and equivalents per share

$1.42

FCF YieldFree cash flow as percentage of market cap

0.44%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 2696.HKFinancial Ratios Analysis details for 2696.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2696.HKSector Benchmarking details for 2696.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Shanghai Henlius Biotech, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Shanghai Henlius Biotech, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Shanghai Henlius Biotech, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Shanghai Henlius Biotech, Inc.

For Shanghai Henlius Biotech, Inc., essential financial indicators include EPS 1.65, PE 40.00, and ROE 0.29. These key ratios reveal insights into Shanghai Henlius Biotech, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Shanghai Henlius Biotech, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Shanghai Henlius Biotech, Inc.

Metrics like Net Margin 14.33% and ROA 7.74% shed light on how well Shanghai Henlius Biotech, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Shanghai Henlius Biotech, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Shanghai Henlius Biotech, Inc.

Using ratios such as P/B Ratio 10.93 and PEG Ratio 3.99, investors can assess whether Shanghai Henlius Biotech, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Shanghai Henlius Biotech, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Shanghai Henlius Biotech, Inc.

Financial health indicators, such as Debt/Equity Ratio 1.21 and Cash Flow $0.27, provide a snapshot of Shanghai Henlius Biotech, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Shanghai Henlius Biotech, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Shanghai Henlius Biotech, Inc.

Investing in Shanghai Henlius Biotech, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Shanghai Henlius Biotech, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;